The drug industry has built a unified wall of resistance to a pricing and transparency push in Maryland, the latest fight over state action against pricey meds.
The New York Attorney General's pushback over hep C drug coverage is finally starting to pay off: After limiting coverage to the sickest patients, seven insurers agreed to cover the meds for almost all commercially insured patients in the state.